KLINIKUM DER UNIVERSITÄT MÜNCHEN

Elisabeth K. Trapp¹, Brigitte Rack¹, Leonie Majunke¹, Julian Koch¹, Simone Hofmann¹, Thomas W.P. Friedl², Julia Neugebauer¹, Julia Jückstock¹, Bernadette Jäger², Jens Huober², Wolfgang Janni², Marianna Alunni-Fabbroni¹

Background

Metastasis are thought to be induced by occult spreading of tumor cells already during the early phases of the disease. Circulating Tumor Cells (CTCs) are regarded as precursors of distant metastasis, while detaching from the primary tumor and originating micrometastases in distant organs. Recent evidences pointed to CTC heterogeneity, showing that CTCs can present different phenotypes. Goal of this study was to identify in metastatic breast cancer (mBC) patients EpCAM negative CTCs and to further characterize them for epithelial (EM), mesenchymal (MM), EMT (EMT-TF), TrkB1 anoikis resistance (AM) and cancer stem cell (CSM) marker expression. A correlation between marker overexpression and clinical parameters was also evaluated.

Median Age Range (year

pT (%)

pN (%)

Histology (%

Metastasis localization

HER2 status

Hormonereceptor sta

Therapy line



CTC posi

CTC neg

Methods

Blood samples were obtained from mBC patients under different lines of therapy. Patients' characteristics are summarized in Table 1. All blood samples, withdrawn at different time points during treatment, were beads depleted of EpCAM⁺ cells and CD45⁺ white blood cells (Figure 1) (Mego et al., Int J Cancer 2012;130(4):808-816) and marker expression was analyzed by qRT-PCR in the EpCAM/CD45 depleted fraction. Beta-actin was used as housekeeping (HK) gene and cDNAs were quantified with the delta-Ct method using the formula: ¹/₂^Ct (target-HK). The highest expression level for each marker found in healthy donors (n=11) was used as threshold value to measure gene overexpression in mBC patients. All blood samples were analyzed in parallel for the presence of EpCAM⁺ CTCs with the CellSearch[™] system (Veridex, Raritan NJ) (Table 2).




Figure 1: Sample processing workflow

Detection of EMT, anoikis and stem cell markers in metastatic breast cancer patients under different lines of treatment

¹Department of Gynecology and Obstetrics, University Hospital Munich, Ludwig-Maximilians-University, 80337 Munich, Germany ²Department of Gynecology and Obstetrics, University Hospital Ulm, 89075 Ulm, Germany

e rs)	62 35-79	
	T1(b-c) pT2-4 n/a	8 (28.6%) 19 (67.8%) 1 (3.6%)
	pNO pN1-3 n/a	9 (32.1%) 13 (46.5%) 6 (21.4%)
%)	G1 G2-3 n/a	0 (0.0%) 23 (82.1%) 5 (17.9%)
l	Viscera Bone Viscera+Bone n/a	8 (28.6%) 8 (28.6%) 11 (39.2%) 1 (3.6%)
S	Negative Positive n/a	20 (71.4%) 7 (25.0%) 1 (3.6%)
atus	Negative Positive n/a	2 (7%) 25 (93%) 1 (3.6%)
е	Endocrine Chemotherapy HER2 Chemo. + HER2 Anti-angiogenic	22 (78.5%) 5 (17.9%) 7 (25.0%) 1 (3.6%) 4 (14.3%)

Table 1: Patient characteristics (n = 28)

CellSearch [™] Analysis (n=28)				
positive		9 (32%)		
negative		19 (68%)		
Table 2: Ep	CAM ⁺ CTC detection			

Results

In the EpCAM/CD45 depleted fractions derived from the 9 CellSearch[™] positive patients, 6 (66%) of the samples were positive for at least one EM, one MM or one EMT-TF (Table 3). Simultaneous overexpression of EM and EMT-TFs in CTCs was observed in 2 (22%) patients. There was no upregulation of TrkB1 or SCM in this group. In the EpCAM/CD45 depleted fractions derived from the 19 CellSearch[™] negative patients, 5 (26%) samples were found positive for at least one EM, 2 (10%) for at least one MM and 4 (21%) for at least one EMT-TF, notably with Zeb1 overexpressed in 3 (16%) samples. No overexpression was found for TrkB1, suggesting that anoikis repression might be regulated by a different mechanism. Interestingly, 9 (47%) samples showed an overexpression of at least one SCM. Co-expression of EM and EMT-TF, EM and SCM or SCM and EMT-TF was observed in 3 (16%), 4 (21%) and 4 (21%) patients respectively, while co-expression of EM, EMT-TF and SCM was found in 3 (16%) patients. A significant association (chi-squared test, p=0.039) was found between SCM and endocrine therapy of the primary tumor: patients presenting SCM overexpression were found less likely to have received an endocrine therapy for their primary tumor (3 out of 9; 33%) as compared to patients with no SCM overexpression (14 out of 18; 78%). No significant association was found in the same group between SCM overexpression and hormone receptor status (p=0.103). Finally, CTCs overexpressing MM were found significantly (p=0.016) more often in patients with a pT4 tumor (3 out of 5; 60%) as compared to patients with pT1 (0 out of 8; 0%), pT2 (1 out of 10; 10%) or pT3 tumors (0 out of 4; 0%). No other correlations between marker expression and clinical parameters were found.

Conclusions

These preliminary results suggest that mBC patients undergoing different lines of therapy present heterogeneous CTCs populations. 12 (63%) patients with undetectable EpCAM⁺ CTCs were found positive for different markers in different combinations in the EpCAM/CD45 depleted blood fraction. These findings underline a high grade of heterogeneity in the CTC population which could explain why mBC patients, at first responding to treatment, might finally relapse, probably because of resistant CTCs subpopulations selection.

This presentation is the intellectual property of the authors. Contact at marianna.alunni@med.uni-muenchen.de for permission to reprint and/or distribute.

EpCAM / CD45 depleted fractions						
Markers	CellSearch [™] positive (n=9)	CellSearch™ negative (n=19)	Total (n = 28)			
EM	2 (22%)	5 (26%)	7 (25%)			
MM	2 (22%)	2 (10%)	4 (14%)			
EMT-TF	2 (22%)	4 (21%)	6 (21%)			
AM	0 (0%)	0 (0%)	0 (0%)			
SCM	0 (0%)	9 (47%)	9 (32%)			
EM + EMT-TF	2 (22%)	3 (16%)	5 (18%)			
EM + SCM	0 (0%)	4 (21%)	4 (14%)			
SCM + EMT-TF	0 (0%)	4 (21%)	4 (14%)			
EM + EMT-TF + SCM	0 (0%)	3 (16%)	3 (11%)			

Table 3: Expression levels of the different markers in EpCAM/CD45 depleted cellular fractions derived from CellSearch[™] positive and negative samples (EM: EpCAM, E-Cadherin, Cytokeratin 18 and 19; MM: N-Cadherin, Vimentin; EMT-TF: Twist1, Snail1, SLUG, Zeb1, FoxC2; AM: TrkB1; SCM: CD24, CD44, CD133)

Acknowledgment

The authors wish to thank Alvera Rengel Puertas and Beate Zill (University Hospital Munich, Ludwig-Maximilians-University) for their technical assistance and all the patients for participating in this translational research study.

